Table 2.
Antiretroviral central nervous system penetration effectiveness (CPE) scoring system used in recent clinical studies
| Increasing CNS penetration → | 0 | 0.5 | 1 |
|---|---|---|---|
| Nucleoside reverse transcriptase inhibitors | Didanosine Tenofovir Zalcitabine Adefovir |
Emtricitabine Lamivudine Stavudine |
Abacavir Zidovudine |
| Nonnucleoside reverse transcriptase inhibitors | Efavirenz | Delavirdine Nevirapine |
|
| Protease inhibitors | Nelfinavir Ritonavir Saquinavir Saquinavir/r Tipranavir/r |
Amprenavir Atazanavir Fosamprenavir Indinavir |
Amprenavir/r Atazanavir/r Fosamprenavir/r Indinavir/r Lopinavir/r |
| Entry inhibitors | Enfuvirtide T-1249 |
Maraviroc Vicriviroc |
|
| Integrase inhibitors | Raltegravir Elvitegravir |
Adapted from Smurzynski et al. 2011; with permission, from Wolters Kluwer Health © 2011.